Company Overview Lonza's global organization, strategy and history make us fit for the future Company Overview Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We focus on enabling treatments that prevent illness and support healthier lifestyles. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers. We provide a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Our scale and resources mean we can provide a one-stop solution for our customers to help people get well, feel well, and stay well. In 2020, we supported more than 820 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules. Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. Our business benefits from global supply chains, but we have worked to maintain the agility to address marketplace needs on a local level. A firm commitment to responsible business and sustainability underpins everything we do. Minimizing our impact on the environment, conserving energy and natural resources, and helping to improve life quality are all central to our culture. Lonza's Vision Zero initiative is a prime example, as we strive to achieve zero workplace accidents and injuries, zero environmental incidents, zero product transportation incidents and zero manufacturing process incidents. We work to attract and retain the best talent, to make a meaningful difference to our own business, as well as the communities in which we operate. Lonza generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. The Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI). We also maintain a secondary listing on the SGX Singapore Exchange. Lonza's response to COVID-19 Our leadership Board of Directors Executive Committee Other Committees Our vision, purpose and strategy Our journey to become the leading healthcare solution provider and help overcome some of the world’s greatest challenges. Read more Our history With more than 120 years of experience, Lonza continues to evolve as a global leader. See our history Our locations Lonza has a global presence, operating across five continents. Find a location Our websites Lonza offers products and services to help patients and consumers through all stages of healthcare. Explore our websites Our Offering Pharma & Biotech Capsules & Health Ingredients About Us Company News and Media Investor Relations Sustainability Events Careers Overview Life at Lonza Career Stories Apply Utilities Contact Legal Disclaimer Privacy Policy Sitemap © 2021 Lonza. All rights reserved. WE VALUE YOUR PRIVACY This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences. MANAGE CHOICES AGREE & PROCEED REJECT ALL Privacy Policy Powered by: Edit Preferences